Peter Wickersham is the Vice President and General Manager of Gilead Sciences UK & Ireland, and a leader in HIV treatment, liver disease, and oncology. With over 25 years in healthcare ...

MedTech Innovator (MTI), the world's largest accelerator of medical technology companies, today announced the addition of Minnetronix Medical, PRIA Healthcare, Prolucid Technologies, RegNav, and Veeva ...

Dr Véronique Walsh, VP and GM at Gilead Sciences UK & Ireland, commented: “This news comes at a time when new hospitals are preparing to deliver CAR-T cell therapies and will mean that ...

Gilead Sciences handily beat the consensus Wall Street earnings estimate for Q4. The company projects much higher earnings in full-year 2025. Income and value investors could like this biotech ...

Gilead forecasts it will generate between $28.2 billion and $28.6 billion in full-year sales in 2025. The company didn't reveal how the lenacapavir PrEP rollout will play into that total number ...

Gilead Sciences (GILD) reported $7.57 billion in revenue for the quarter ended December 2024, representing a year-over-year increase of 6.4%. EPS of $1.90 for the same period compares to $1.72 a ...

Gilead Sciences, Inc. (Nasdaq: GILD) announced today its results of operations for the fourth quarter and full year 2024. "Gilead delivered another exceptionally ...

Gilead Sciences Inc (Symbol: GILD) has been named as a Top 25 ''Dividend Giant'' by ETF Channel, with a stunning $22.93B worth of stock held by ETFs, and above-average ''DividendRank'' statistics ...

Intel chairman Frank Yeary has been in dramatic talks with senior Trump administration officials as indications are that the ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

Apple and Intel also managed modest gains, helping limit losses in the Nasdaq Composite. Daily Gilead Sciences, Inc CVS Health surged 13.6% after posting stronger-than-expected Q4 earnings ...